Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | KMO | O15229 | 3/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485520 | 1.00 | HTR2A (0.39) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL3514316 | 0.89 | CHEK1 (0.43) | HTR2AHTR2CHTR2BDGAT1KMO | |
| SCHEMBL30272867 | 0.89 | CHEK1 (0.43) | HTR2AHTR2CHTR2BDGAT1KMO | |
| SCHEMBL22463061 | 0.88 | HTR2A (0.42) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL18031893 | 0.86 | HTR2A (0.40) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL2318217 | 0.84 | KMO (0.48) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL30855572 | 0.84 | HTR2A (0.36) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL2144622 | 0.84 | HTR2A (0.36) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL30385717 | 0.84 | KMO (0.48) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL16437423 | 0.84 | KMO (0.50) | HTR2AHTR2CHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-3617205-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113004278-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-107438607-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-02-05 | — | — | CN | disclosed |
| US-10632126-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3259269-B9 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617205-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190269693-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2019-09-05 | — | — | US | disclosed |
| EP-3259269-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10251892-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | HTR2A 1267/4885HTR2C 1572/4885HTR2B 1749/4885 |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | HTR2A 1843/4885HTR2C 1200/4885HTR2B 1372/4885 |
| US-10251892-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | HTR2A 4611/4885HTR2C 3014/4885HTR2B 3937/4885 |
| US-10632126-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | HTR2A 4611/4885HTR2C 3014/4885HTR2B 3937/4885 |
| US-20190269693-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | HTR2A 4611/4885HTR2C 3014/4885HTR2B 3937/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | HTR2A 1267/4885HTR2C 1572/4885HTR2B 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.